CKD-9001 / Chong Kun Dang - LARVOL DELTA

Discovery and characterization of CKD-9001, a novel PARP1-selective inhibitor and DNA trapper with enhanced efficacy and an improved toxicity profile in HRD cancers (AACR 2026) - "In this study, we present the preclinical development of CKD-9001, a novel PARP1-selective inhibitor and potent DNA trapper.We developed CKD-9001, a next-generation PARP1-selective inhibitor, and evaluated its preclinical efficacy and toxicity profile against the leading agents, olaparib and saruparib. Furthermore, pharmacokinetic and safety analyses confirmed that CKD-9001 markedly reduced hematologic toxicity and significantly improved the safety margin compared with conventional pan-PARP inhibitors. In addition, we found that CKD-9001 was capable of penetrating the blood-brain barrier (BBB).In conclusion, CKD-9001 is a next-generation PARP1-selective inhibitor that successfully combines enhanced efficacy with remarkably low toxicity, demonstrating outstanding therapeutic potential in HRD cancers."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD • PARP2